Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Comirnaty"

23 News Found

India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
News | July 11, 2022

India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData

Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small

Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants
News | June 14, 2022

Sanofi-GSK next-gen COVID-19 booster delivers strong immune response against main variants

Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile

USFDA grants full approval for Pfizer-BioNTech Covid-19 vaccine
News | August 23, 2021

USFDA grants full approval for Pfizer-BioNTech Covid-19 vaccine

The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease

Latest Stories

Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management

Bayer wins Japan nod for finerenone in broad heart failure population

China approves first-in-class TGCT drug, marking global first for pimicotinib

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging